Document is current
Any future updates will be listed below
-
Authors
Ng, Soo Chin
Moon, Joon-Ho
Park, Sung Soo
Koh, Youngil
Lee, Ji Hyun
Eom, Hyeon-Seok
Shin, Ho-Jin
Jung, Sung Hoon
Do, Young Rok
Wilfred, Gilbert
Husin, Azlan
Kim, Hyo Jung
Abdul Wahid, SFadilah
Lee, Myung-Won
Heo, Hye-won
Kim, Kihyun https://orcid.org/0000-0002-5878-8895
Chuncharunee, Suporn
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals International AG Singapore Branch
- License Information
-
More Information
Article History
Received: 23 August 2024
Revised: 16 January 2025
Accepted: 16 January 2025
First Online: 20 March 2025
Declarations
:
: Hye-won Heo was an employee of Takeda Pharmaceuticals Korea Co., Ltd. Ji Hyun Lee has received honoraria/research funding from Takeda, Amgen, Janssen, Celgene-BMS, Sanofi and JW Pharmaceutical, and was a consultant for Takeda, Amgen and Janssen. Youngil Koh holds a leadership position at Genome Opinion, holds stock/options in Genome Opinion, Curocell, Proteina and Tomocube, and has received research funding from Sanofi-Genzyme and Roche. Soo Chin Ng has received consultation fees/honorarium for participation in advisory boards from Roche, AstraZeneca, Novartis and BeiGene. The other authors have no conflicts of interest to declare.
